Coronary disease & ACSRandomised controlled trial
Long-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial
- Randomised controlled trial
- multicentre (Japan and Switzerland)
- superiority
Authors' conclusion
The use of BP-EES for primary PCI in patients presenting with STEMI was not superior to DP-EES regarding frequency of neoatherosclerosis at 3 years.
Study context
- Population
- STEMI patients undergoing primary PCI178 with optical coherence tomography (OCT) at 3 years
- Participants
- 239 patients
- Comparison
- Biodegradable polymer everolimus-eluting stent (EES) vs durable polymer EES
- BP-EESn = 119
- DP-EESn = 117reference
- Primary endpoint
- Frequency of neoatherosclerosis by OCT (fibroatheroma, fibrocalcific plaque or macrophage accumulation within the neointima)
- Follow-up
- 3 years
Primary result
Neoatherosclerosis
Odds ratio
0.83
95% CI 0.33–2.04
P = 0.69
By group
BP-EES vs DP-EES
OR 0.83 (95% CI 0.33–2.04); P = 0.69
As reported in the abstract
Further findings
Fibroatheroma · 3 years
P = 0.66
Macrophage accumulation · 3 years
P = 0.68
Fibrocalcific neoatherosclerosis · 3 years
- No fibrocalcific neoatherosclerosis observed
Safety
Target lesion failure
P = 0.97
Original publication
Long-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial. Eur Heart J. Published 1 September 2024. doi:10.1093/eurheartj/ehae589
Summarised from the published abstract; every number is checked against it